Juniper Pharmaceuticals

Juniper Pharmaceuticals is developing therapeutics that address unmet medical needs in women’s health. The Company's current pipeline leverages the 505(b)(2) regulatory pathway with new formulations of existing pharmaceuticals. Juniper's current intravaginal ring product candidates are JNP-0101, an oxybutynin IVR for the treatment of overactive bladder in women; JNP-0201, a combination estrogen + progesterone IVR for menopausal symptoms; and, JNP-0301, a progesterone IVR for the prevention of preterm birth in women with a short cervical length at mid-pregnancy.

Company Growth (employees)
Boston, US
Size (employees)
139 (est)
Juniper Pharmaceuticals was founded in 1986 and is headquartered in Boston, US

Juniper Pharmaceuticals Office Locations

Juniper Pharmaceuticals has an office in Boston
Boston, US (HQ)
33 Arch St

Juniper Pharmaceuticals Financials and Metrics

Juniper Pharmaceuticals Financials

Juniper Pharmaceuticals's revenue was reported to be $54.6 m in FY, 2016

Revenue (Q2, 2017)

14 b

Gross profit (Q2, 2017)

6.3 b

Gross profit margin (Q2, 2017), %


Net income (Q2, 2017)

(376 m)

EBIT (Q2, 2017)

(356 m)

Market capitalization (13-Dec-2017)

55.3 m

Cash (30-Jun-2017)

21.5 m


37.8 m
Juniper Pharmaceuticals's current market capitalization is $55.3 m.
USDFY, 2013FY, 2014FY, 2015FY, 2016


29.2 m32.5 m37.6 m54.6 m

Revenue growth, %


Cost of goods sold

13.3 m17.7 m21.4 m24.3 m

Gross profit

16 m14.8 m16.1 m30.3 m
USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017


7.1 m7.2 m6.9 m11.5 m8.3 m10.2 b11.5 b12.1 m11.9 m11.6 m11.2 b14 b

Cost of goods sold

3.2 m4.3 m3.9 m5.1 m4.9 m5.6 b6.4 b6.4 m6.5 m5.7 m6.6 b7.7 b

Gross profit

3.9 m3 m3 m6.4 m3.4 m4.6 b5 b5.8 m5.4 m5.9 m4.7 b6.3 b

Gross profit Margin, %

USDFY, 2013FY, 2014FY, 2015FY, 2016


20.7 m16.8 m13.9 m21 m

Accounts Receivable

7.2 m5.3 m181 k


2.6 m3.2 m3.6 m5.6 m

Current Assets

32.2 m26.4 m26.7 m34.7 m
USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017


18.8 m12.2 m11.8 m16.4 m16.3 m16.1 m17.4 m13.5 m13 m15 m21.8 m21.5 m

Accounts Receivable

6.8 m7.3 m7.2 m5.3 m4.8 m6.5 m7.9 m8 m6.2 m5.3 m4.5 m6.9 m


2 m2.4 m3.6 m2.9 m3.3 m3.8 m3.1 m3.2 m3.9 m4.8 m5.7 m5.2 m

Current Assets

31.4 m23.2 m24 m25.8 m26.1 m28.6 m30.7 m27.5 m26.4 m26.4 m33.5 m35.4 m
USDFY, 2013FY, 2014FY, 2015FY, 2016

Net Income

6.7 m3.4 m(2.1 m)6 m

Depreciation and Amortization

919.1 k2 m1.9 m1.9 m

Accounts Receivable

(2.3 m)1.7 m(2.5 m)192 k


46.5 k(619 k)(424 k)(2 m)
USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017

Net Income

744.2 k429 k622 k4.3 m(692 k)(1 m)(65 k)362 k(1.7 m)248 k(1.4 b)

Depreciation and Amortization

376.5 k448 k949 k1.5 m523 k1 m1.5 m

Accounts Receivable

(2 m)(17 k)149 k1.9 m353 k(1.1 m)(2.7 m)8 m6.2 m5.3 m4.5 m


635.4 k178 k(966 k)(273 k)(130 k)(579 k)94 k3.2 m3.9 m4.8 m5.7 m
Y, 2017


-0.1 x

Financial Leverage

1.5 x
Show all financial metrics

Juniper Pharmaceuticals Operating Metrics

FY, 2016

Patents Issued

Show all operating metrics

Juniper Pharmaceuticals Market Value History

Juniper Pharmaceuticals's Web-traffic and Trends

Juniper Pharmaceuticals Company Life and Culture

You may also be interested in